A Big Step Toward Curbing Graft-vs.-Host Disease After Bone Marrow Transplant
This post originally appeared on Discoveries, the blog of Boston Children’s Hospital. A drug used for rheumatoid arthritis has moved a step closer to U.S. Food and Drug Administration (FDA) approval for a desperately needed new use. The drug, abatacept, has gained FDA breakthrough therapy designation for preventing acute, severe graft-versus-host disease (GVHD) in patients receiving bone … Read more